UNSPSC 51283710: Cefuzonam

This classification denotes a cephalosporin antibiotic with the molecular formula C16H15N7O5S4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 860MT00T7T, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-8-oxo-3-((1,2,3-thiadiazol-5-ylthio)methyl)-, (6r-(6alpha,7beta(z)))- but generally known as cefuzonam, which bears US NIH Compound Identifier 6336505.

UNSPSC 51283710 Cefuzonam is a Commodity code that does not align with the state and local opportunities currently being solicited under it. The source shows recent procurement activity tagged to this code that involves naloxone, safe drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and over-the-counter products—none of which are cefuzonam (a third-generation cephalosporin antibiotic). The mismatch suggests either a data-entry error in the tagging of these opportunities or a misclassification at the state or local issuing level. The actual goods being procured under these solicitations span emergency medical supplies, pharmaceutical benefit programs, and generic drug sourcing rather than the specific antibiotic indicated by the code name.

The issuing bodies include a county health department (Seminole County, Florida), a state health and human services commission (Texas HHS), a municipal fire department (City of Tampa), and a multi-state cooperative purchasing alliance (MMCAP, administered by Minnesota Department of Administration). Recent opportunities include an IFB from Seminole County for naloxone and drug deactivation systems due July 26, 2026; an RFI from Texas HHS posted April 3, 2026, on direct-to-manufacturer prescription programs; an ITB from Tampa Fire Rescue for medical and first aid supplies (169 line items, estimated $700,000, small-business set-aside) due March 13, 2026; and an RFP from MMCAP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, spanning multiple states including Oregon. Given the code-to-opportunity disconnect, firms evaluating this code should verify their UNSPSC categorization with issuing bodies and focus upstream on pharmaceutical sourcing and emergency medical supply contracting families where the actual procurement activity is concentrated.